Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.64 (proteinase K)
 4,071 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

70-S ribosomes and 50-S ribosomal subunits from Escherichia coli D10 were treated with proteinase K for increasing periods of time. Peptidyl transferase activity and sparsomycin-induced binding of (U)C-A-C-C-A-[3H]Leu-Ac were tested in the treated particles, the binding of the substrate being more sensitive to the protease than peptide bond formation. Comparison of the amounts of proteins present in the treated particles with the residual activity indicates that only proteins L3 and L14 are released at a similar rate to that at which peptidyl transferase activity is lost. Proteins related to this ribosomal activity by other techniques are lost at a faster rate than the activity itself. In addition, the results indicate that sparsomycin stimulates the binding of the substrate by a different mechanism from that which inhibits peptide bond formation.
 ...
PMID:Peptidyl transferase of bacterial ribosome: resistance to proteinase K. 36 57

The C-peptides used to prevent HIV infection, such as T20 and C34, are chemically synthesized, making them costly drugs. The sensitivity of peptides to protease also restricts their clinical application. We showed previously that C52L, a recombinant peptide produced in bacteria, is a potent anti-HIV C-peptide, although most of the peptide accumulates in inclusion bodies. Here we applied leucine and glutamine scanning mutagenesis to the heptad-repeat of C52L to produce an optimized variant of C52L that is potent and soluble when expressed in bacteria. We present that the substitution of Asn656 and Glu659 with leucine (peptide L14 and L15, respectively) can increase the helical content of this peptide. These substitutions also result in soluble expression. We measured the inhibitory activities of these mutant peptides against laboratory-adapted HIV-1 strains and found that L15 and its parental peptide C52L have equivalent anti-HIV activities. Moreover, L15 was found to be more stable to proteinase K digestion than C52L. Thus, we show that the L15 peptide can be expressed in a soluble state and exhibits potent anti-HIV activity. This peptide may be further developed as an anti-HIV therapeutic and/or microbicide for the prevention of HIV sexual transmission.
 ...
PMID:Glu659Leu substitution of recombinant HIV fusion inhibitor C52L induces soluble expression in Escherichia coli with equivalent anti-HIV potency. 2147 77